Advertisement

Chinese Journal of Integrative Medicine

, Volume 16, Issue 2, pp 102–108 | Cite as

Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: A prospective randomized controlled study

  • Hua-qin Tian (田华琴)
  • Hong-liang Li (李宏良)
  • Bin Wang (王 斌)
  • Gui-wen Liang (梁贵文)
  • Xiao-qing Huang (黄小青)
  • Zhi-qing Huang (黄志庆)
  • Jiang-ming Lang (郎江明)
  • Yu-ping Zhang (张玉萍)
  • Xue-zhang Chen (陈学彰)
  • Yin-song Chen (陈银崧)
Original Article

Abstract

Objective

To observe the efficacy of Chinese medicine comprehensive therapeutic project in treating the middle/late stage primary hepatic carcinoma (PHC).

Methods

With prospective randomized controlled design, 97 patients with PHC were assigned to the test group (49 cases) treated with Chinese medicine comprehensive therapy using Oleum fructus bruceas intervention combining oral intake of Ganji Decoction (肝积方) and external application of Ailitong (癌理通), and the control group (48 cases) treated with chemotherapeutic agents combining iodized oil chemo-embolization and analgesics. The immediate and long-term efficacy, adverse reaction, pain-relieving initial time (PRIT) and pain-relieving sustained time (PRST) of the treatment, as well as the change in relieving patients’ quality of life (QOL) were observed.

Results

The difference between the two groups in illness control rate was statistically insignificant (P>0.05), but the adverse reaction occurence rate in the test group was lesser than that in the control group (P<0.05). PRIT was insignificantly different in the two groups (P>0.05), but the PRST was significantly superior in the test group than that in the control group (10.37±2.18 h vs 7.78±1.95 h, P<0.01). After treatment, the increased Karnofsky scores in the test group indicated that the patients’ somatic activity, symptoms and QOL were improved significantly, which were significantly superior to those in the control group (P<0.05). The survival rate in the two groups was similar at the 3rd month after treatment, but the test group did show superiority in terms of half- and 1-year survival rate (65.9% vs 42.5% and 38.6% vs 18.1%, respectively, P<0.05). The median survival time in the test group was 8.9 months and that in the control group was 5.3 months.

Conclusion

Chinese medicine comprehensive therapy is an effective treatment for the middle/late stage patients of PHC, and it could extend the PRST, improve the patients’ QOL and long-term survival with less adverse reaction.

Keywords

hepatic cancer Chinese medical treatment comprehensive therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    National Cancer Prevention and Control Office, Chinese Anti-cancer Association. Standardized diagnosis and treatment of common malignant tumors in China. Volume 2. Beijing: Joint Press of Beijing Medical University and Peking Union Medical College, 1990:54–55.Google Scholar
  2. 2.
    Sun Y, ed. Medical oncology. Beijing: People’s Medical Publishing House, 2001:995–996.Google Scholar
  3. 3.
    Wang CH, Fang JQ, Zhang CZ, Lin Y, Luo YM. Establishment and evaluation of measuring scale of QOL on hepatoma. Chin J Behav Med (Chin) 1998;37:170–173.Google Scholar
  4. 4.
    Ko KH, Jo M, Lee JH. Antiinflammatory and analgesic activities, and slin irritation test of piroxicam patch. J Appl Pharmacol 1994;2:71–76Google Scholar
  5. 5.
    Liu LM, Yang YF, eds. Grababin medicinarum particularum of oncology. Beijing: People’s Medical Publishing House, 2003:651–652.Google Scholar
  6. 6.
    Jiang WQ, Sun XF, Zhang L, Huang HQ. Practical manual of prescription on oncology. Guangzhou: Guangdong Science and Technology Press, 2003:524–528.Google Scholar
  7. 7.
    Yamada R, Sato M, Kawabata M. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397.PubMedGoogle Scholar
  8. 8.
    Chen XM, Luo PF, Hu JL, Shao PJ, Zhou ZJ. Delayed adverse reactions of liver after transcatheter hepatic arterial chemoembolization with anticancer drugs mixed lipiodol. Cancer (Chin) 1994;13:50–52.Google Scholar
  9. 9.
    Gao QY. Prospective, controlled study of chemoembolization expectant treatment on hepatoma. Foreign Med Sci (Oncol Sec, Chin) 1995;22:313.Google Scholar
  10. 10.
    Wang F, Cao Y, Liu HY, Fu ZD, Han R. Study of Brucea javanica oil emulsion induced HL-60 cell apoptosis. Chin J Tradit Chin Med (Chin) 2003;28:759–762.Google Scholar
  11. 11.
    Wang H, Zhang B, Wu GJ, Zhang G, Xin JG. Brucea mouse anticancer at the role of bladder cancer. J Fourth Milit Med Univ (Chin) 2001;22:1886.Google Scholar
  12. 12.
    Lin HY, Wu JM, Zhang WS. Study progress of oleum fructus bruceae. Chin J Exp Pharmacol Tradit Chin Med Form (Chin) 2006;12:65–69.Google Scholar
  13. 13.
    Li WJ, Deng L, Ai LX, Li JP. Oleum of brucea javanicalipidol used in hepatic arterial embolization to treat hepatocellular carcinoma: an effect analysis. Imag Diagn intervent radiol (Chin) 2005;14:30–31.Google Scholar
  14. 14.
    Ma L, Zhang YN. Effects of seminal oil emulsion of Brucea javanica on apoptosis and apoptosis-related genes in human hepatocellular carcinoma cells. World Chin J Digestol (Chin) 2004;12:559–562.Google Scholar
  15. 15.
    Wu WY. The application of Chinese medicine in interventional transcatheter arterial treatment of liver cancer. Chin J Integr Tradit West Med Liver Dis (Chin) 1998;8:188–191.Google Scholar
  16. 16.
    Shen YJ, Chen CX, eds. Pharmacology of traditional Chinese medicine. Shanghai: Shanghai Science and Technology Press; 2008: 58–61, 125–127, 320–324.Google Scholar
  17. 17.
    Huang XQ, Tian HQ, Liang GW. Affection of the drug of Ganjifang containing serum to the hepG2 cell proliferation. Chin J Pract Med (Chin) 2006;19:2613–2615.Google Scholar
  18. 18.
    Chen XZ, Tian HQ, Huang XQ, Liang GW, Huang ZQ. Effect of Ganjifang to blood stasis of patients with advanced PLC. Shaanxi Tradit Chin Med (Chin) 2005;26:891–893.Google Scholar
  19. 19.
    Tian HQ, Xu XQ, Liang GW, Huang ZQ, Deng JM. Effect of Ganjifang to SIL-2R and T cells of patients with advanced PLC. Chin J Mod Med (Chin) 2001;11(10):89–90.Google Scholar
  20. 20.
    Tian HQ, Liang GW, Huang XQ, Huang ZQ. Effect of Ganjifang combined with Argon-helium cryoablation and TACE treating 48 patients with advanced PLC. New J Tradit Chin Med (Chin) 2005;37:21–22.Google Scholar
  21. 21.
    Tian HQ, Liang GW, Tao Y, Huang ZQ, Yu SY, Ye WY. Interventional treatment of liver cancer with traditional Chinese medicine clinical research. Henan J Tradit Chin Med (Chin) 2001;16:47–48.Google Scholar
  22. 22.
    Liu JX, Xu DF, Fang ZZ. Effect of Chansu Ointment for cancer pain. J Tradit Chin Med (Chin) 1993;34:281–282.Google Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Hua-qin Tian (田华琴)
    • 1
  • Hong-liang Li (李宏良)
    • 1
  • Bin Wang (王 斌)
    • 1
  • Gui-wen Liang (梁贵文)
    • 1
  • Xiao-qing Huang (黄小青)
    • 1
  • Zhi-qing Huang (黄志庆)
    • 1
  • Jiang-ming Lang (郎江明)
    • 1
  • Yu-ping Zhang (张玉萍)
    • 1
  • Xue-zhang Chen (陈学彰)
    • 1
  • Yin-song Chen (陈银崧)
    • 1
  1. 1.Department of OncologyFoshan Municipal Hospital of Traditional Chinese MedicineGuangdongChina

Personalised recommendations